

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer

Hai-Yuan Yang¹, Yi-Rong Liu¹, Ding Ma¹, Xin Hu¹, Jian Zhang², Zhong-Hua Wang², Geng-Hong Di^{1*}, Xi-Chun Hu², Zhi-Ming Shao¹

Supplementary Figure 1. Bootstrap resampling with 10,000 times verified interaction between the OS benefit and DRFI as a continuous covariate. Red dashed lines: 95%CI estimated using 10,000 bootstrap samples; Blue line: original data; Blue dashed lines: 95%CI estimated using original data; Grey lines: first 1000 bootstrap samples.

